Added to YB: 2026-10-02
Pitch date: 2026-09-22
CMHC.SW [neutral]
Cosmo N.V.
-9.9%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
Market Cap
CHF 1.0B
Pitch Price
CHF 57.60
Price Target
N/A
Dividend
3.60%
EV/EBITDA
416.64
P/E
-151.39
EV/Sales
7.96
Sector
Pharmaceuticals
Category
growth
Cosmo Pharmaceuticals (CMHC Switzerland): GI Genius - let's go!
CMHC.SW (update): Cosmo’s GI Genius gains a stronger commercial foundation from CADeNCE, the largest randomized real-world colonoscopy detection study to date: across 334,000+ procedures, access increased adenoma-detection odds by 22% and the detection rate to 54.9% from 50.7%. The Veterans Health Administration subsequently expanded computer-aided detection across its colonoscopy centers, but near-term adoption still depends on purchasing, reimbursement and market-by-market implementation.
Read full article (2 min)